PLXP PLx Pharma Inc.

2.51
-0.21  -8%
Previous Close 2.72
Open 2.77
Price To Book -1.9
Market Cap 22,982,213
Shares 9,156,260
Volume 12,863
Short Ratio
Av. Daily Volume 9,851
Stock charts supplied by TradingView

NewsSee all news

  1. PLx Pharma Inc. Reports Fourth Quarter 2019 Results and Provides Regulatory Update on VAZALORE

    -- Planning a Bioequivalence Study to Support VAZALORE 325 mg sNDA -- -- Announces $8 Million Convertible Preferred Stock Financing with Park West and MSD Partners -- SPARTA, New Jersey, March 13, 2020 (GLOBE

  2. PLx Pharma Inc. to Discuss 2019 Fourth Quarter and Full Year Financial Results on March 13, 2020 Conference Call

    SPARTA, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its

  3. PLx Pharma Inc. Presents Original Abstract and Simultaneous Publication of its Novel, Liquid-Filled Capsule Aspirin Formulation at the 2020 International Stroke Conference

    SPARTA, N.J., Feb. 21, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its

  4. Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium™ 2020

    CARMIEL, Israel, Jan. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant

  5. PLx Pharma Inc. to Present at Biotech Showcase 2020

    SPARTA, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 top-line data did not meet endpoints - October 25, 2016.
Locilex
Mild infections of diabetic foot ulcers
sNDA filing due following bioequivalence study. Meeting with FDA scheduled for April at which point an updated timeline will be provided.
VAZALORE
Aspirin - cardiovascular and stroke patients patients

Latest News

  1. PLx Pharma Inc. Reports Fourth Quarter 2019 Results and Provides Regulatory Update on VAZALORE

    -- Planning a Bioequivalence Study to Support VAZALORE 325 mg sNDA -- -- Announces $8 Million Convertible Preferred Stock Financing with Park West and MSD Partners -- SPARTA, New Jersey, March 13, 2020 (GLOBE

  2. PLx Pharma Inc. to Discuss 2019 Fourth Quarter and Full Year Financial Results on March 13, 2020 Conference Call

    SPARTA, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its

  3. PLx Pharma Inc. Presents Original Abstract and Simultaneous Publication of its Novel, Liquid-Filled Capsule Aspirin Formulation at the 2020 International Stroke Conference

    SPARTA, N.J., Feb. 21, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its

  4. Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium™ 2020

    CARMIEL, Israel, Jan. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant

  5. PLx Pharma Inc. to Present at Biotech Showcase 2020

    SPARTA, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and

  6. PLx Pharma Inc. Provides Regulatory Update on VAZALORE

    -- PLx Aligning with the FDA on Data Requirements for VAZALORE -- FDA Approves Labeling for 325 mg -- -- Expect to Launch VAZALORE in late 2020 -- SPARTA, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc.

  7. PLx Pharma Inc. Reports Third Quarter 2019 Results

    SPARTA, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and

  8. PLx Pharma Inc. to Discuss 2019 Third Quarter Financial Results on November 8, 2019 Conference Call

    SPARTA, N.J., Oct. 28, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and

  9. PLx Pharma Inc. Presents Moderated Abstract and Simultaneous Publication on the Pharmacokinetic and Pharmacodynamics (PK/PD) Properties of its Novel, Liquid Aspirin Formulation at the 2019 European Society of Cardiology Congress

    SPARTA, N.J. and PARIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing more effective and safer products

  10. PLx Pharma Inc. to Present at Janney Healthcare Conference 2019 on September 10

    SPARTA, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and